Outcomes for cardiac surgery at Mt. View 2017

1. Major Procedures Mortality CABG, Valve, and Valve+CABG Procedures Combined1 Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Number of Cases - 33 143 74,094 164,896 Mortality Summary In-hospital Mortality ................................... - 3.0% 1.4% 2.2% 2.0% Operative Mortality ................................... - 3.0% 2.1% 2.9% 2.6% Mortality Risk-Adjustment2 In-hospital Mortality Odds Ratio ............................................ - 1.07 0.79 1.27 1.00 Lower 95% Confidence Limit .............. - 0.44 0.39 1.14 - Upper 95% Confidence Limit .............. - 2.60 1.61 1.41 - O/E Ratio ............................................... - 1.60 0.54 1.10 1.00 Lower 95% Confidence Limit .............. - 0.09 0.01 1.05 - Upper 95% Confidence Limit .............. - 8.13 1.42 1.16 - Risk-adjusted Rate ................................ - 3.1% 1.1% 2.2% 2.0% Operative Mortality Odds Ratio ............................................ - 1.02 0.81 1.30 1.00 Lower 95% Confidence Limit .............. - 0.46 0.42 1.18 - Upper 95% Confidence Limit .............. - 2.26 1.57 1.43 - O/E Ratio ............................................... - 1.24 0.62 1.11 1.00 Lower 95% Confidence Limit .............. - 0.07 0.07 1.08 - Upper 95% Confidence Limit .............. - 6.40 1.42 1.17 - Risk-adjusted Rate ................................ - 3.0% 1.6% 2.8% 2.5% 1 Includes all 7 Major Procedure Categories (CABG, AVR, AVR+CABG, MVR, MVR+CABG, MVP, MVP+CABG) 2 Refer to the Report Overview for information on risk-adjustment methodology Risk-adjustment is not performed on time periods of less than 6 months Major Procedures -- 7

2. Major Procedures -- 8

3. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Number of Cases - 32 116 54,881 116,231 Demographics Age (years) Mean ..................................................... - 72.7 69.1 65.6 65.6 Median ................................................... - 72.5 70.0 66.0 66.0 25th Percentile ....................................... - 68.5 63.0 59.0 59.0 75th Percentile ....................................... - 78.0 76.0 73.0 73.0 Age >= 65 years old .............................. - 87.5% 66.4% 56.7% 56.5% Gender, Female ........................................ - 9.4% 25.9% 24.5% 24.5% Missing .................................................. - 0.0% 0.0% 0.0% 0.0% Race1 Caucasian ............................................. - 93.8% 97.4% 83.3% 82.7% Black ...................................................... - 0.0% 0.0% 6.6% 7.4% Asian ..................................................... - 0.0% 0.0% 3.7% 3.5% Native American .................................... - 3.1% 2.6% 0.8% 0.6% Native Hawaiian/Pacific Islander ........... - 0.0% 0.0% 0.5% 0.5% Other ..................................................... - 0.0% 1.7% 3.8% 3.4% Multiple Races ....................................... - 0.0% 2.6% 1.2% 0.9% Missing / Not Documented .................... - 3.1% 0.9% 2.5% 2.9% Pt. Declined to Disclose2 ....................... - 3.1% 0.9% 0.5% 0.6% Hispanic or Latino or Spanish Ethnicity .... - 28.1% 36.2% 9.2% 7.4% Missing/ Not Documented ..................... - 6.3% 0.9% 4.1% 4.1% Body Mass Index3 Underweight (BMI < 18.5) ...................... - 0.0% 0.9% 0.7% 0.7% Normal (BMI 18.5 - 24.9) ....................... - 28.1% 18.1% 17.3% 17.7% Overweight (BMI 25.0 - 29.9) ................ - 28.1% 37.1% 37.0% 36.9% Obese I (BMI 30.0 - 34.9) ...................... - 34.4% 31.0% 26.9% 27.0% Obese II (BMI 35.0 - 39.9) ..................... - 9.4% 7.8% 11.7% 11.6% Morbid Obesity (BMI 40.0+) ................... - 0.0% 5.2% 6.3% 6.0% Missing Height ....................................... - 0.0% 0.0% 0.1% 0.1% 1 Data presented in the report represent the individual response rates for each race category Missing Weight ...................................... - 0.0% 0.0% 0.1% 0.1% shown; summing the individual non-caucasian categories will not result in the same rates as shown in the graph since non-caucasian, as defined for the graph, does not include races or ethnicities reported in combination with caucasian 2 Option added in v2.81 3 BMI = Weight(kg) / Height(m)2 CABG -- 9

4. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Comorbidities Diabetes Mellitus ...................................... - 46.9% 51.7% 49.4% 49.3% Diet Control ........................................ - 0.0% 1.7% 2.9% 2.8% Oral Control ........................................ - 12.5% 14.7% 22.4% 22.3% Insulin Control .................................... - 25.0% 34.5% 18.0% 18.2% Other SQ Medication Control1 ............ - 0.0% 0.0% 0.4% 0.4% Other Control ...................................... - 0.0% 0.0% 0.1% 0.1% Missing Control ................................... - 13.3% 1.7% 0.9% 0.8% Missing .................................................. - 3.1% 0.9% 0.2% 0.2% Hypertension ............................................ - 71.9% 87.9% 89.4% 89.4% Missing .................................................. - 3.1% 0.9% 0.2% 0.2% Dyslipidemia ............................................. - 71.9% 79.3% 89.6% 90.2% Missing .................................................. - 3.1% 3.4% 0.3% 0.3% Family History of CAD .............................. - 50.0% 44.8% 23.3% 20.6% Missing .................................................. - 9.4% 24.1% 4.3% 4.4% Current/Recent Cigarette Smoker ............ - 9.4% 21.6% 22.6% 22.0% Smoker, Current Status Unknown1 ........ - 6.3% 0.9% 0.5% 0.5% Missing .................................................. - 6.3% 11.2% 0.6% 0.6% Chronic Lung Disease Mild ........................................................ - 3.1% 12.9% 10.1% 9.5% Moderate ............................................... - 3.1% 11.2% 5.2% 4.6% Severe ................................................... - 0.0% 6.9% 4.2% 4.0% Unknown Severity1 ................................ - 21.9% 27.6% 7.4% 7.1% Missing .................................................. - 25.0% 16.4% 3.1% 2.7% Congestive Heart Failure .......................... - 3.1% 36.2% 17.7% 18.4% CHF / NYHA Class I2 .......................... - 3.1% 20.7% 1.5% 1.9% CHF / NYHA Class II .......................... - 0.0% 8.6% 5.2% 5.7% CHF / NYHA Class III ......................... - 0.0% 5.2% 7.2% 7.4% CHF / NYHA Class IV ......................... - 0.0% 0.9% 4.2% 4.1% CHF / Missing Class ........................... - 0.0% 2.4% 2.6% 2.6% 1 Option added in v2.81 Missing .................................................. - 0.0% 22.4% 1.2% 1.0% 2 NYHA Class is only collected for patients with CHF % represents proportion of cases that had both CHF and the indicated NYHA class Peripheral Arterial Disease ....................... - 3.1% 15.5% 13.9% 13.9% Missing .................................................. - 3.1% 8.6% 0.9% 0.5% CABG -- 10

5. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Cerebrovascular Disease ......................... - 15.6% 26.7% 21.7% 21.6% Missing ............................................... - 0.0% 0.9% 0.9% 0.8% Coma/Nonresponsive State ................... - 0.0% 1.7% 0.3% 0.2% Missing ............................................... - 0.0% 0.0% 0.9% 1.0% CVD TIA ................................................ - 6.3% 3.4% 4.3% 4.3% Missing ............................................... - 0.0% 6.0% 1.3% 1.1% Carotid Stenosis1 None ................................................... - 87.5% 80.2% 85.9% 86.5% 50-79%2 .............................................. - 0.0% 12.9% 10.0% 9.6% 80-100% ............................................. - 0.0% 5.2% 2.1% 2.1% Missing/Not Documented ................... - 12.5% 1.7% 1.9% 1.8% CVD Prior Carotid Surgery .................... - 9.4% 0.9% 3.4% 3.4% Missing ............................................... - 0.0% 0.9% 1.0% 0.9% Cerebrovascular Accident ..................... - 0.0% 6.9% 7.6% 7.9% Missing ............................................... - 0.0% 4.3% 1.1% 0.9% Renal Failure, Dialysis-Dependent ........... - 0.0% 3.4% 3.2% 3.2% Missing ............................................... - 3.1% 0.9% 0.2% 0.2% Last Creatinine Preop ............................... Mean ..................................................... - 1.0 1.2 1.2 1.2 Median ................................................... - 0.8 0.9 1.0 1.0 25th Percentile ....................................... - 0.8 0.8 0.8 0.8 75th Percentile ....................................... - 1.0 1.2 1.2 1.2 Missing .................................................. - 0.0% 0.0% 0.3% 0.3% Value >= 4.0 mg/dL ............................... - 0.0% 1.7% 2.4% 2.5% Immunosuppressive Treatment ................ - 3.1% 0.0% 3.1% 3.3% Missing ............................................... - 3.1% 2.6% 0.7% 0.5% Previous Interventions 1 Defined as highest level of occlusion in either carotid. Previous Cardiac Surgery3 ....................... - 0.0% 6.9% 2.2% 2.4% 2 Option added in v2.81 First reoperation .................................... - 0.0% 6.9% 2.1% 2.4% 3 Previous cardiac surgery reflects any prior CABG, valve, or other cardiac surgery Previous CABG ........................................ - 0.0% 5.2% 1.6% 1.8% CABG -- 11

6. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Previous AICD .......................................... - 0.0% 0.9% 1.0% 1.0% Previous Pacemaker ................................. - 0.0% 5.2% 1.7% 1.8% Previous PCI ............................................. - 15.6% 31.0% 30.7% 30.9% <= 6 hours prior to surgery .................... - 0.0% 1.7% 1.1% 0.9% > 6 hours prior to surgery ...................... - 15.6% 29.3% 29.5% 29.9% Missing timing ........................................ - 0.0% 0.0% 0.3% 0.2% Previous PCI Stent ................................... - 100.0% 91.7% 85.9% 87.4% Status Surgery Status Elective .................................................. - 28.1% 43.1% 37.7% 37.4% Urgent .................................................... - 50.0% 53.4% 57.7% 58.5% Emergent ............................................... - 21.9% 3.4% 4.4% 3.9% Emergent Salvage ................................. - 0.0% 0.0% 0.2% 0.2% Missing .................................................. - 0.0% 0.0% 0.0% 0.0% MI .............................................................. - 25.0% 42.2% 54.5% 54.0% <= 7 days prior to surgery .................. - 21.9% 23.3% 31.3% 29.8% 8-21 days prior to surgery .................. - 0.0% 3.4% 5.1% 5.4% >21 days prior to surgery .................... - 3.1% 15.5% 17.9% 18.7% Missing timing ..................................... - 0.0% 0.0% 0.1% 0.1% Missing .................................................. - 0.0% 13.8% 0.9% 0.6% Cardiogenic Shock At the time of surgery ......................... - 15.6% 0.9% 1.5% 1.5% Within 24 hrs of surgery1 .................... - 3.1% 0.9% 0.6% 0.5% Missing .................................................. - 0.0% 0.0% 0.1% 0.1% Resuscitation <= 1 hr prior to surgery ........................ - 0.0% 0.0% 0.3% 0.3% 1-24 hrs prior to surgery1 ....................... - 0.0% 0.0% 0.5% 0.4% Missing .................................................. - 0.0% 0.0% 0.1% 0.1% 1 Option added in v2.81 CABG -- 12

7. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Cardiac Pres. on Admission No Symptoms or Angina ........................ - 3.1% 3.4% 7.7% 7.5% Stable Angina ........................................ - 25.0% 27.6% 14.4% 15.1% Unstable Angina .................................... - 34.4% 31.9% 35.3% 35.8% Non-ST Elevation MI (Non-STEMI) ....... - 21.9% 29.3% 28.9% 27.8% ST Elevation MI (STEMI) ....................... - 6.3% 3.4% 5.6% 5.2% Angina Equivalent1 ................................ - 6.3% 0.9% 3.4% 3.5% Other1 .................................................... - 3.1% 3.4% 4.6% 5.0% Missing .................................................. - 0.0% 0.0% 0.1% 0.1% Any Arrhythmia2 ........................................ - 18.8% 18.1% 13.9% 13.9% Recent ................................................... - 18.8% 12.9% 11.3% 11.3% Remote .................................................. - 0.0% 3.4% 2.1% 2.2% Missing .................................................. - 3.1% 3.4% 0.3% 0.3% Ventricular Tachycardia/Fibrillation3 ...... - 3.1% 1.7% 3.2% 3.3% Missing ............................................... - 0.0% 0.0% 0.3% 0.2% 3rd degree Heart Block3 ......................... - 0.0% 1.7% 0.6% 0.6% Missing ............................................... - 0.0% 0.0% 0.4% 0.3% Atrial Fibrillation3, 4 ................................. - 15.6% 8.6% 9.4% 9.4% Missing ............................................... - 0.0% 0.0% 0.3% 0.3% Atrial Flutter3, 4 ....................................... - 0.0% 0.9% 1.1% 1.1% Missing ............................................... - 0.0% 0.0% 0.4% 0.2% Hemodynamics and Catheterization Number of Diseased Coronary Vessels One ........................................................ - 0.0% 4.3% 3.7% 3.8% Two ........................................................ - 31.3% 16.4% 18.9% 19.0% Three ..................................................... - 62.5% 74.1% 76.5% 76.3% Missing .................................................. - 6.3% 5.2% 0.9% 0.8% Left Main Disease (>=50% Stenosis) ........ - 43.8% 32.8% 32.2% 31.5% Missing .................................................. - 50.0% 61.2% 34.5% 37.7% 1 Option added in v2.81 2 Includes VTach/VFib, 2nd and 3rd degree HB, Sick Sinus Syndrome, AFib, and Aflutter 3 For v2.81 data, includes recent or remote arrhythmias 4 For v2.81 data, AFib and AFlutter were separated. CABG -- 13

8. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Ejection Fraction Mean ..................................................... - 55.6 48.0 52.0 52.1 Median ................................................... - 60.0 50.0 55.0 55.0 25th Percentile ....................................... - 55.0 35.0 45.0 45.0 75th Percentile ....................................... - 60.0 60.0 60.0 60.0 EF missing or not measured .................. - 21.9% 7.8% 3.2% 2.8% EF <40%1 .............................................. - 8.0% 26.2% 15.5% 15.3% Pulmonary Hypertension2 ......................... - 50.0% 39.2% 34.9% 34.0% PA mean/systolic pressure missing or not measured .................................... - 93.8% 56.0% 66.6% 68.3% Aortic Stenosis .......................................... - 0.0% 5.2% 3.6% 3.5% Missing .................................................. - - 0.0% 0.2% 0.1% Mitral Insufficiency Trivial ..................................................... - 6.3% 23.3% 26.2% 29.1% Mild ........................................................ - 0.0% 27.6% 25.8% 25.7% Moderate ............................................... - 6.3% 10.3% 6.4% 6.5% Severe ................................................... - 0.0% 0.0% 0.5% 0.5% Missing/Not Documented ...................... - - 0.0% 0.5% 0.6% Preoperative Medications Aspirin ....................................................... - 78.1% 68.1% 84.6% 84.4% Among Eligible Cases ........................... - 78.1% 69.9% 85.3% 85.1% Contraindicated / Not Indicated ............. - 0.0% 2.6% 0.8% 0.8% Missing .................................................. - 0.0% 3.4% 0.8% 0.7% Inotropics .................................................. - 6.3% 1.7% 1.4% 1.2% Missing .................................................. - 0.0% 0.0% 0.3% 0.2% Beta Blockers ........................................... - 46.9% 61.2% 88.6% 89.5% Among Eligible Cases ........................... - 45.8% 64.2% 94.2% 95.3% Contraindicated / Not Indicated ............. - 3.1% 6.0% 5.2% 5.5% Missing .................................................. - 0.0% 0.0% 0.0% 0.1% 1 Among patients with measured EF 2 PA systolic pressure > 35mmHg Steroids .................................................... - 6.3% 5.2% 2.0% 2.0% Among Eligible Cases ........................... - 6.3% 5.2% 2.1% 2.0% Contraindicated / Not Indicated ............. - 0.0% 0.0% 0.0% 0.0% Missing .................................................. - 0.0% 0.0% 0.4% 0.4% CABG -- 14

9. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Nitrates IV ................................................. - 21.9% 12.1% 9.2% 8.7% Missing .................................................. - 0.0% 0.0% 0.4% 0.4% ACE Inhibitors ........................................... - 40.6% 24.1% 42.7% 40.4% Among Eligible Cases ........................... - 40.6% 25.0% 43.5% 41.1% Contraindicated / Not Indicated ............. - 0.0% 3.4% 1.9% 1.7% Missing .................................................. - 0.0% 0.9% 0.8% 0.8% Anticoagulants .......................................... - 62.5% 42.2% 43.4% 43.8% Missing .................................................. - 0.0% 0.0% 0.4% 0.4% Coumadin1 ................................................ - 0.0% 0.0% 0.3% 0.3% Missing .................................................. - 0.0% 0.0% 0.5% 0.5% Coumadin w/in 5 Days2 ............................ - - 2.2% 0.5% 0.4% Among Eligible Cases ........................... - - 2.2% 0.5% 0.4% Contraindicated / Not Indicated ............. - - 0.0% 0.1% 0.1% Missing .................................................. - - 0.0% 0.9% 0.7% Lipid-Lowering agents ............................... - 68.8% 37.1% 78.8% 79.0% Among Eligible Cases ........................... - 68.8% 37.1% 79.8% 80.1% Contraindicated / Not Indicated ............. - 0.0% 0.0% 1.3% 1.3% Missing .................................................. - 3.1% 0.9% 0.8% 0.8% Glycoprotein IIb/IIIa Inhibitor ..................... - 6.3% 0.9% 1.6% 1.3% Missing .................................................. - 3.1% 0.0% 0.4% 0.4% ADP Inhibitors within 5 Days .................... - 3.1% 16.4% 9.0% 9.4% Among Eligible Cases ........................... - 3.1% 16.4% 9.0% 9.5% Contraindicated / Not Indicated ............. - 0.0% 0.0% 0.1% 0.2% Missing .................................................. - 3.1% 1.7% 0.4% 0.5% ADP Inhibitor Discontinuation3 < 1 Day ............................................... - 0.0% 5.3% 14.1% 14.3% 1 Day .................................................. - 0.0% 42.1% 15.5% 17.0% 2 Days ................................................ - 0.0% 31.6% 17.4% 17.6% 1 Variable dropped in v2.9 3 Days ................................................ - 0.0% 0.0% 19.0% 19.3% 2 Variable added in v2.9 4 Days ................................................ - 0.0% 21.1% 20.2% 19.4% 3 Excludes patients not on ADP Inhibitors within 5 Days 5 Days ................................................ - 100.0% 0.0% 12.4% 11.4% Missing .................................................. - 0.0% 0.0% 1.3% 0.9% CABG -- 15

10. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Antiplatelets within 5 Days1 ...................... - 0.0% 0.0% 4.2% 3.5% Among Eligible Cases ........................... - 0.0% 0.0% 4.2% 3.5% Contraindicated / Not Indicated ............. - 0.0% 0.0% 0.1% 0.2% Missing .................................................. - 0.0% 1.4% 0.5% 0.5% Operative Information Blood Products Used ................................ - 75.0% 26.7% 26.5% 25.8% Number of Blood Product Units Used 1 Red Blood Cell Unit ......................... - 18.8% 6.0% 5.6% 6.0% 2 Red Blood Cell Units ....................... - 18.8% 6.0% 7.7% 7.2% 3 Red Blood Cell Units ....................... - 3.1% 5.2% 2.7% 2.4% 4+ Red Blood Cell Units ..................... - 21.9% 3.4% 2.6% 2.4% 1+ Fresh Frozen Plasma Units ........... - 40.6% 13.8% 7.6% 6.8% 1+ Cryoprecipitate Units ..................... - 6.3% 6.9% 2.5% 2.6% 1+ Platelet Units ................................. - 37.5% 12.1% 13.7% 13.2% Missing .................................................. - 0.0% 0.0% 0.7% 0.7% Number of Distal Anastamoses, Total 1 ............................................................ - 9.4% 33.6% 5.0% 5.3% 2 ............................................................ - 25.0% 24.1% 17.6% 17.7% 3 ............................................................ - 50.0% 23.3% 39.7% 40.0% 4 ............................................................ - 15.6% 15.5% 28.0% 27.8% 5+ .......................................................... - 0.0% 3.4% 9.4% 9.0% Missing2 ................................................. - 0.0% 0.0% 0.1% 0.1% Vein Harvest Technique3 Endovascular/Endoscopic ..................... - 100.0% 94.9% 89.9% 91.2% Direct Vision .......................................... - 0.0% 3.4% 8.4% 7.2% Both ....................................................... - 0.0% 1.7% 1.5% 1.3% Cryopreserved ....................................... - 0.0% 0.0% 0.1% 0.0% Missing ............................................... - 0.0% 0.0% 0.2% 0.2% Internal Mammary Artery Used4 Any ........................................................ - 93.8% 100.0% 98.8% 99.0% Left ..................................................... - 84.4% 67.3% 93.2% 93.1% Right ................................................... - 0.0% 2.7% 0.4% 0.4% 1 Variable dropped in v2.9 Both .................................................... - 9.4% 30.0% 4.8% 5.0% 2 Where number of arterial conduits and number of vein grafts both missing Missing .................................................. - 0.0% 0.0% 0.1% 0.1% 3 Where at least 1 vein was harvested 4 Excludes patients with prior CABG surgery CABG -- 16

11. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Radial Artery Used ................................... - 0.0% 0.0% 4.8% 5.0% Missing .................................................. - 0.0% 0.0% 0.5% 0.5% Radial Artery Harvest Technique ........... Endovascular/Endoscopic .................. - - - 45.9% 43.1% Direct Vision ....................................... - - - 49.3% 53.1% Both .................................................... - - - 0.8% 0.5% Missing ............................................... - - - 4.0% 3.3% IABP Used ................................................ - 25.0% 16.4% 9.8% 9.1% Preop .................................................. - 18.8% 15.5% 7.4% 6.7% Intraop ................................................ - 6.3% 0.0% 2.1% 2.0% Postop ................................................ - 0.0% 0.9% 0.4% 0.4% Missing Timing ................................... - 0.0% 0.0% 0.0% 0.0% Missing .................................................. - 0.0% 0.0% 0.2% 0.2% Robotic Technology Assisted ................... - 6.3% 50.9% 0.6% 1.0% Missing .................................................. - 0.0% 0.0% 0.3% 0.7% Off-pump Procedure (see following section for detail) ................................... - 34.4% 44.0% 13.2% 12.5% Cross-Clamp Time (min) Mean ..................................................... - 75.6 - 71.1 69.2 Median ................................................... - 77.0 - 66.0 65.0 25th Percentile ....................................... - 51.0 - 49.0 48.0 75th Percentile ....................................... - 94.0 - 88.0 86.0 Cardiopulmonary Bypass Time (min) Mean ..................................................... - 110.8 53.2 97.3 94.7 Median ................................................... - 111.0 49.0 92.0 89.0 25th Percentile ....................................... - 84.0 37.0 71.0 69.0 75th Percentile ....................................... - 125.0 64.0 118.0 114.0 CABG -- 17

12. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Circulatory Arrest ...................................... - 0.0% 0.0% 0.4% 0.3% Missing .................................................. - 0.0% 0.0% 0.1% 0.3% Circulatory Arrest Time (min) Mean ..................................................... - - - 10.8 11.3 Median ................................................... - - - 4.0 5.0 25th Percentile ....................................... - - - 0.0 0.0 75th Percentile ....................................... - - - 9.0 11.0 Skin Incision Duration (min) Mean ..................................................... - 261.4 230.9 240.0 235.7 Median ................................................... - 237.0 219.0 231.0 227.0 25th Percentile ....................................... - 200.0 189.0 187.0 183.0 75th Percentile ....................................... - 269.0 263.0 282.0 278.0 OR Duration (min) Mean ..................................................... - 348.1 327.3 320.2 315.5 Median ................................................... - 316.0 309.0 310.0 305.0 25th Percentile ....................................... - 274.0 281.0 260.0 255.0 75th Percentile ....................................... - 351.5 353.0 369.0 364.0 Antibiotic Selection1, 2 ............................... - 100.0% 100.0% 99.4% 99.4% Exclusions ............................................. - 0.0% 0.0% 0.7% 0.7% Missing .................................................. - 0.0% 0.0% 0.0% 0.1% Antibiotic Timing1, 3 ................................... - 100.0% 100.0% 99.0% 98.9% Exclusions ............................................. - 0.0% 0.0% 0.4% 0.4% Missing .................................................. - 0.0% 0.0% 0.0% 0.1% Antibiotics Discontinued1,4 ........................ - 100.0% 99.1% 99.0% 99.1% Exclusions ............................................. - 0.0% 0.0% 1.4% 1.1% Missing .................................................. - 0.0% 0.0% 0.0% 0.1% Clotting Agents5 ........................................ - 3.1% 19.8% 84.5% 84.0% Missing .................................................. - 0.0% 0.0% 0.4% 0.9% 1 All antibiotic measures are calculated among patients without exclusions 2 First or second generation cephalosporin prescribed/given prophylactically 3 Appropriate timing of prophylactic antibiotics 4 Prophylactic antibiotics discontinued within 48 hours 5 Includes one or more of the following: Aprotinin, Epsilon Amino-Caproic Acid, Desmopressin, or Tranexamic Acid CABG -- 18

13. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Postoperative Information Blood Products Used ................................ - 65.6% 37.1% 29.8% 28.7% Number of Blood Product Units Used 1 Red Blood Cell Unit ......................... - 15.6% 12.1% 10.0% 10.0% 2 Red Blood Cell Units ....................... - 28.1% 10.3% 9.4% 8.5% 3 Red Blood Cell Units ....................... - 12.5% 5.2% 3.0% 2.9% 4+ Red Blood Cell Units ..................... - 9.4% 7.8% 5.0% 4.8% 1+ Fresh Frozen Plasma Units ........... - 9.4% 6.0% 6.6% 6.2% 1+ Cryoprecipitate Units ..................... - 3.1% 5.2% 2.9% 3.2% 1+ Platelet Units ................................. - 3.1% 8.6% 7.2% 7.2% Missing .................................................. - 0.0% 0.0% 0.1% 0.1% Intraop/Postop Products Used .................. - 87.5% 44.0% 42.5% 41.3% Total Number of Blood Product Units 1 Red Blood Cell Unit ......................... - 12.5% 7.8% 9.5% 9.8% 2 Red Blood Cell Units ....................... - 18.8% 10.3% 11.7% 10.8% 3 Red Blood Cell Units ....................... - 18.8% 8.6% 5.2% 5.0% 4+ Red Blood Cell Units ..................... - 37.5% 12.9% 10.0% 9.4% 1+ Fresh Frozen Plasma Units ........... - 40.6% 16.4% 12.6% 11.6% 1+ Cryoprecipitate Units ..................... - 6.3% 8.6% 5.1% 5.5% 1+ Platelet Units ................................. - 37.5% 15.5% 18.5% 18.0% Missing .................................................. - 0.0% 0.0% 0.0% 0.0% Ventilation Total Ventilation Hours Mean .................................................. - 28.2 9.0 17.1 16.8 Median ............................................... - 8.7 5.3 5.7 5.7 25th Percentile .................................... - 5.8 0.5 3.8 3.9 75th Percentile .................................... - 18.8 10.8 10.9 10.3 Initial Ventilation Hours Mean .................................................. - 18.9 7.5 12.1 11.8 Median ............................................... - 8.1 5.1 5.6 5.6 Initial Ventilation <6 hours .................. - 25.0% 58.6% 54.3% 54.8% Extubated in OR .................................... - 3.1% 25.0% 2.8% 2.3% Missing .................................................. - 0.0% 0.0% 0.2% 0.2% Reintubation .......................................... - 6.3% 5.2% 3.8% 3.5% Missing .................................................. - 0.0% 0.0% 0.2% 0.2% CABG -- 19

14. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Additional Ventilation Hours1 Mean .................................................. - 144.0 29.2 131.7 141.2 Median ............................................... - 144.0 14.5 64.0 66.2 ICU Stay Total ICU Hours Mean .................................................. - 134.8 142.3 77.9 72.3 Median ............................................... - 120.3 121.5 51.7 48.0 75th Percentile .................................... - 93.4 96.3 29.1 26.0 25th Percentile .................................... - 142.7 164.2 93.5 81.0 Initial ICU Hours Mean .................................................. - 134.8 141.1 74.8 68.9 Median ............................................... - 120.3 121.3 51.0 47.6 Readmitted to ICU ................................. - 0.0% 0.9% 2.5% 2.8% Additional ICU Hours2 Mean .................................................. - - 144.0 124.4 123.9 Median ............................................... - - 144.0 71.1 70.7 Mortality Summary In-hospital Mortality ................................... - 3.1% 0.9% 1.9% 1.7% Operative Mortality ................................... - 3.1% 1.7% 2.5% 2.3% Mortality Risk-Adjustment3 In-hospital Mortality Odds Ratio ............................................ - 1.08 0.80 1.20 1.00 Lower 95% Confidence Limit .............. - 0.43 0.39 1.06 - Upper 95% Confidence Limit .............. - 2.68 1.64 1.36 - O/E Ratio ............................................... - 1.63 0.40 1.08 1.00 Lower 95% Confidence Limit .............. - 0.09 0.02 1.02 - Upper 95% Confidence Limit .............. - 7.79 2.12 1.15 - Risk-adjusted Rate ................................ - 2.7% 0.7% 1.9% 1.7% 1 Among patients reintubated 2 Among patients readmitted to the ICU 3 Refer to the Report Overview for information on risk-adjustment methodology Risk-adjustment is not performed on time periods of less than 6 months CABG -- 20

15. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Operative Mortality Odds Ratio ............................................ - 1.02 0.83 1.21 1.00 Lower 95% Confidence Limit .............. - 0.45 0.42 1.08 - Upper 95% Confidence Limit .............. - 2.31 1.64 1.35 - O/E Ratio ............................................... - 1.26 0.61 1.09 1.00 Lower 95% Confidence Limit .............. - 0.07 0.11 1.03 - Upper 95% Confidence Limit .............. - 6.05 2.07 1.14 - Risk-adjusted Rate ................................ - 2.7% 1.4% 2.5% 2.3% Complications Summary Any Complications .................................... - 43.8% 52.6% 38.6% 38.9% Any Major Complications / Operative Mortality ................................................. - 21.9% 12.9% 12.9% 12.0% Operative Complications Any Reoperation .................................... - 0.0% 2.6% 3.6% 3.7% Any Reoperation (NQF Definition)1 ........ - 0.0% 1.7% 2.4% 2.4% Reoperation for Bleeding ....................... - 0.0% 1.7% 1.7% 1.7% Reoperation for Valvular Dysfunction2 ... - 0.0% 0.0% 0.0% 0.0% Reoperation for Graft Occlusion2 ........... - 0.0% 0.0% 0.3% 0.3% Aortic Reintervention3 ............................ - - 0.0% 0.0% 0.0% Reoperation for Other Cardiac .............. - 0.0% 0.0% 0.4% 0.4% Reoperation for Other Non-Cardiac ....... - 0.0% 0.9% 1.4% 1.5% Infection Complications Any Infection .......................................... - 12.5% 15.5% 2.4% 2.3% Deep Sternal Infection/Mediastinitis ...... - 0.0% 0.0% 0.3% 0.3% Septicemia/Sepsis ................................. - 0.0% 1.7% 0.9% 0.9% Conduit Harvest or Cannulation Site4 .... - 12.5% 6.9% 0.5% 0.5% 1 Includes reoperations for bleeding/tamponade, valvular dysfunction, graft occlusion, and other cardiac problems. 2 Includes surgical and PCI/Transcatheter interventions 3 Variable added in 2.9 4 Excludes patients with zero vein grafts 5 Variable dropped in 2.9 CABG -- 21

16. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Neurological Complications Any Neurological ................................... - 9.4% 12.1% 3.1% 3.0% Coma/Encephalopathy1 ......................... - 9.4% 4.3% 1.8% 1.6% Coma2 ................................................... - - 0.0% 1.3% 1.3% Encephalopathy2 ................................... - - 0.0% 0.2% 0.2% Permanent Stroke .................................. - 0.0% 0.0% 1.4% 1.4% Transient Ischemic Attack ..................... - 0.0% 0.9% 0.2% 0.2% Paralysis ................................................ - 0.0% 0.0% 0.2% 0.1% Pulmonary Complications Any Pulmonary ...................................... - 25.0% 16.4% 12.6% 12.1% Prolonged Ventilation ............................ - 18.8% 10.3% 8.2% 7.5% Pneumonia ............................................ - 9.4% 2.6% 2.7% 2.4% Pulmonary Embolism ............................. - 0.0% 0.0% 0.2% 0.2% Pleural Effusion Requiring Drainage ...... - 3.1% 4.3% 3.3% 3.6% Renal Complications Renal Failure3 ........................................ - 0.0% 0.9% 2.4% 2.1% Vascular Complications Any Vascular ......................................... - 0.0% 0.9% 0.3% 0.4% Acute Limb Ischemia ............................. - 0.0% 0.9% 0.3% 0.4% Other Complications Any Other .............................................. - 28.1% 28.4% 29.9% 30.5% New Onset Atrial Fibrillation4 ................. - 33.3% 26.4% 24.6% 25.0% Recent Recurrent Atrial Fibrillation5 ....... - 0.0% 0.0% 26.6% 26.9% Cardiac Arrest ....................................... - 3.1% 3.4% 2.1% 1.9% Anticoagulant Complication ................... - 0.0% 0.0% 0.6% 0.5% Tamponade ........................................... - 0.0% 0.0% 0.1% 0.1% Gastro-Intestinal Complication .............. - 0.0% 0.0% 2.1% 2.1% Multi-System Failure .............................. - 0.0% 0.0% 0.7% 0.6% 1 Variable dropped in 2.9 2 Variable added in 2.9 3 Excludes patients with preoperative dialysis or last creatinine >=4 4 New Onset Afib is only among patients with no history of arrhythmias 5 Recent Recurrent Afib is among patients with history of recent Afib CABG -- 22

17. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Complications Risk-Adjustment1 Major Complications or Op. Mortality Odds Ratio ............................................ - 1.24 0.87 1.07 1.00 Lower 95% Confidence Limit .............. - 0.66 0.55 0.99 - Upper 95% Confidence Limit .............. - 2.32 1.37 1.15 - O/E Ratio ............................................... - 1.51 0.87 1.06 1.00 Lower 95% Confidence Limit .............. - 0.70 0.53 1.04 - Upper 95% Confidence Limit .............. - 2.60 1.33 1.08 - Risk-adjusted Rate ................................ - 18.3% 10.5% 12.7% 12.0% Any Reoperation Odds Ratio ............................................ - 0.82 0.86 0.90 1.00 Lower 95% Confidence Limit .............. - 0.38 0.49 0.82 - Upper 95% Confidence Limit .............. - 1.76 1.51 0.97 - O/E Ratio ............................................... - 0.00 0.63 0.97 1.00 Lower 95% Confidence Limit .............. - 0.00 0.16 0.94 - Upper 95% Confidence Limit .............. - 2.54 1.77 1.02 - Risk-adjusted Rate ................................ - 0.0% 2.3% 3.6% 3.7% Deep Sternal Infection/Mediastinitis Odds Ratio ............................................ - 0.97 0.84 0.84 1.00 Lower 95% Confidence Limit .............. - 0.26 0.22 0.66 - Upper 95% Confidence Limit .............. - 3.64 3.18 1.05 - O/E Ratio ............................................... - 0.00 0.00 0.92 1.00 Lower 95% Confidence Limit .............. - 0.00 0.00 0.82 - Upper 95% Confidence Limit .............. - 33.75 6.92 1.11 - Risk-adjusted Rate ................................ - 0.0% 0.0% 0.3% 0.3% Permanent Stroke Odds Ratio ............................................ - 0.94 0.86 0.96 1.00 Lower 95% Confidence Limit .............. - 0.43 0.48 0.86 - Upper 95% Confidence Limit .............. - 2.05 1.56 1.07 - O/E Ratio ............................................... - 0.00 0.00 1.00 1.00 Lower 95% Confidence Limit .............. - 0.00 0.00 0.94 - Upper 95% Confidence Limit .............. - 7.65 2.28 1.08 - Risk-adjusted Rate ................................ - 0.0% 0.0% 1.4% 1.4% 1 Refer to the Report Overview for information on risk-adjustment methodology Risk-adjustment is not performed on time periods of less than 6 months CABG -- 23

18. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Renal Failure Odds Ratio ............................................ - 0.82 0.76 1.23 1.00 Lower 95% Confidence Limit .............. - 0.30 0.31 1.09 - Upper 95% Confidence Limit .............. - 2.19 1.85 1.40 - O/E Ratio ............................................... - 0.00 0.41 1.12 1.00 Lower 95% Confidence Limit .............. - 0.00 0.02 1.07 - Upper 95% Confidence Limit .............. - 4.48 2.14 1.19 - Risk-adjusted Rate ................................ - 0.0% 0.9% 2.4% 2.1% Prolonged Ventilation Odds Ratio ............................................ - 1.54 1.05 1.11 1.00 Lower 95% Confidence Limit .............. - 0.71 0.60 1.01 - Upper 95% Confidence Limit .............. - 3.33 1.82 1.23 - O/E Ratio ............................................... - 1.91 1.05 1.07 1.00 Lower 95% Confidence Limit .............. - 0.82 0.59 1.05 - Upper 95% Confidence Limit .............. - 3.47 1.69 1.11 - Risk-adjusted Rate ................................ - 15.1% 7.9% 8.1% 7.5% Discharge Location1 Home ..................................................... - 48.4% 62.6% 75.8% 78.3% Extended Care/TCU .............................. - 51.6% 33.9% 19.7% 17.7% Other Acute Care Hospital ..................... - 0.0% 0.9% 0.8% 0.6% Nursing Home ....................................... - 0.0% 2.6% 3.1% 2.7% Hospice ................................................. - 0.0% 0.0% 0.1% 0.1% Left AMA2 .............................................. - 0.0% 0.0% 0.1% 0.1% Other ..................................................... - 0.0% 0.0% 0.3% 0.3% Missing .................................................. - 0.0% 0.0% 0.2% 0.3% Discharge Medications1 Aspirin ....................................................... - 83.9% 87.0% 96.8% 97.1% Among Eligible Cases ........................... - 83.9% 90.9% 98.0% 98.3% Contraindicated / Not Indicated ............. - 0.0% 4.3% 1.3% 1.2% Missing .................................................. - 0.0% 0.0% 0.1% 0.1% ACE inhibitors ........................................... - 83.9% 52.2% 38.4% 35.4% 1 Excludes in-hospital mortalities Among Eligible Cases ........................... - 86.7% 80.0% 65.6% 61.6% 2 Option added in v2.81 Contraindicated / Not Indicated ............. - 3.2% 34.8% 41.5% 42.6% Missing .................................................. - 0.0% 0.0% 0.2% 0.2% CABG -- 24

19. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Beta Blockers ........................................... - 90.3% 92.2% 94.1% 94.5% Among Eligible Cases ........................... - 90.3% 93.8% 98.0% 98.5% Contraindicated / Not Indicated ............. - 0.0% 1.7% 3.9% 4.0% Missing .................................................. - 0.0% 0.0% 0.1% 0.1% Statin Lipid-Lowering Agents .................... - 93.5% 81.7% 94.3% 94.4% Among Eligible Cases ........................... - 93.5% 83.9% 97.5% 97.8% Contraindicated / Not Indicated ............. - 0.0% 2.6% 3.3% 3.4% Missing .................................................. - 0.0% 0.0% 0.1% 0.1% Non-Statin Lipid-Lowering Agents ............ - 0.0% 2.6% 10.3% 10.5% Among Eligible Cases ........................... - 0.0% 2.6% 10.3% 10.6% Contraindicated / Not Indicated ............. - 3.2% 0.0% 0.5% 0.7% Missing .................................................. - 0.0% 0.0% 0.2% 0.2% ADP Inhibitors ........................................... - 12.9% 13.0% 14.4% 13.9% Among Eligible Cases ........................... - 12.9% 13.0% 14.5% 14.0% Contraindicated / Not Indicated ............. - 0.0% 0.0% 0.5% 0.8% Missing .................................................. - 0.0% 0.0% 0.2% 0.2% P2Y12 Antagonists1 .................................. - 38.7% 17.1% 30.6% 31.9% Among Eligible Cases ........................... - 38.7% 17.1% 30.8% 32.3% Contraindicated / Not Indicated ............. - 0.0% 0.0% 0.8% 1.2% Missing .................................................. - 0.0% 0.0% 0.1% 0.1% Other Antiplatelets .................................... - 0.0% 1.7% 1.4% 1.1% Among Eligible Cases ........................... - 0.0% 1.7% 1.4% 1.1% Contraindicated / Not Indicated ............. - 0.0% 0.0% 0.2% 0.6% Missing .................................................. - 0.0% 0.0% 0.2% 0.2% Amiodarone .............................................. - 35.5% 32.2% 34.7% 32.9% Among Eligible Cases ........................... - 35.5% 32.5% 34.9% 33.3% Contraindicated / Not Indicated ............. - 0.0% 0.9% 0.7% 1.0% Missing .................................................. - 0.0% 0.0% 0.2% 0.2% Coumadin ................................................. - 0.0% 0.9% 6.6% 7.2% 1 Variable dropped in v2.9 Among Eligible Cases ........................... - 0.0% 0.9% 6.6% 7.3% Contraindicated / Not Indicated ............. - 0.0% 0.0% 0.3% 0.6% Missing .................................................. - 0.0% 0.0% 0.2% 0.2% CABG -- 25

20. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Discharge Referrals/Counseling1 Cardiac Rehabilitation Referral ................. - 93.5% 93.0% 89.5% 89.6% Missing .................................................. - 0.0% 0.0% 0.3% 0.2% Smoking Cessation Counseling ................ - 44.4% 92.9% 89.0% 90.8% Missing .................................................. - 0.0% 0.0% 0.7% 0.7% 1 Excludes in-hospital mortalities and Not Applicable Records CABG -- 26

21. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Readmission and Reason1 Readmitted within 30 days2 ................... - 16.1% 15.7% 10.6% 10.1% Anticoagulation Complication Valvular ........................................... - 0.0% - - - Pharmacological .............................. - 0.0% 0.9% 0.1% 0.1% Arryhthmia/Heart Block ...................... - 0.0% 1.7% 0.8% 0.9% Congestive Heart Failure .................... - 0.0% 1.7% 1.2% 1.1% MI and/or Recurrent Angina ............... - 0.0% 0.0% 0.3% 0.3% Pericardial Effusion / Tamponade ...... - 0.0% 0.0% 0.2% 0.2% Pneumonia3 ........................................ - 6.5% 0.9% 0.5% 0.5% Respiratory Complications, Other3 ..... - 3.2% 1.7% 0.4% 0.3% Pleural Effusion req. Intervention3 ...... - 0.0% 0.0% 0.8% 0.8% Coronary Artery Dysfunction .............. - 0.0% 0.0% 0.1% 0.1% Valve Dysfunction ............................... - 0.0% 0.0% 0.0% 0.0% Infection - Deep Sternum ................... - 0.0% 0.0% 0.3% 0.4% Infection - Conduit Harvest Site .......... - 0.0% 0.9% 0.3% 0.2% Renal failure ....................................... - 0.0% 0.0% 0.1% 0.1% TIA / Permanent CVA ......................... - 0.0% 0.9% 0.3% 0.3% Acute Vascular Complication ............. - 0.0% 0.0% 0.1% 0.1% Subacute Endocarditis ....................... - 0.0% 0.0% 0.0% 0.0% VAD Complication .............................. - - 0.0% - - Transplant Rejection .......................... - - 0.0% 0.0% 0.0% DVT .................................................... - 0.0% 0.0% 0.1% 0.1% PE ...................................................... - 0.0% 0.0% 0.5% 0.4% Angina4 ............................................... - - 0.0% 0.3% 0.3% Aortic Complication4 ........................... - - 0.0% 0.0% 0.0% Blood Pressure4 ................................. - - 0.0% 0.3% 0.3% Chest Pain, noncardiac4 ..................... - - 0.0% 0.4% 0.3% Depression/psychiatric issue4 ............. - - 0.0% 0.0% 0.0% Electrolyte imbalance4 ........................ - - 0.0% 0.1% 0.1% Failure to Thrive4 ................................ - - 0.0% 0.0% 0.0% GI Issue4 ............................................. - - 0.0% 0.6% 0.6% Mental Status Changes4 ..................... - - 0.0% 0.1% 0.1% Pericarditis/Post Cardiotomy Syndr.4 . - - 0.0% 0.0% 0.0% Renal Insufficency4 ............................. - - 0.0% 0.0% 0.0% Sepsis4 ............................................... - - 2.2% 0.3% 0.2% 1 Excludes in-hospital mortalities Transfusion4 ....................................... - - 0.0% 0.1% 0.0% 2 Timed from discharge for v2.81 Wound, other4 .................................... - - 2.2% 0.5% 0.6% 3 Option added in v2.81 Other .................................................. - 6.5% 5.2% 3.3% 3.2% 4 Option added in v2.9 Other - Planned readmission3 ............ - 0.0% 0.0% 0.1% 0.1% Missing/Unknown .................................. - 0.0% 0.0% 3.5% 3.8% CABG -- 27

22. Isolated CABG Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Length of Stay Summary Total Length of Stay (days) Mean ..................................................... - 8.8 9.2 9.4 9.3 Median ................................................... - 7.0 8.0 8.0 8.0 25th Percentile ....................................... - 6.0 5.5 6.0 6.0 75th Percentile ....................................... - 9.0 11.0 11.0 11.0 Post-Procedure Length of Stay (days) Mean ..................................................... - 7.1 6.8 6.9 6.9 Median ................................................... - 6.0 6.0 6.0 6.0 25th Percentile ....................................... - 5.0 4.0 5.0 5.0 75th Percentile ....................................... - 7.0 8.0 7.0 7.0 PLOS <6 days ....................................... - 31.3% 47.4% 46.2% 46.9% PLOS >14 days ..................................... - 3.1% 5.2% 5.0% 5.0% Length of Stay Risk-Adjustment1 Short stay: PLOS <6 days Odds Ratio ............................................ - 0.75 1.56 1.09 1.00 Lower 95% Confidence Limit .............. - 0.37 1.06 0.96 - Upper 95% Confidence Limit .............. - 1.51 2.29 1.24 - O/E Ratio ............................................... - 0.79 1.26 0.99 1.00 Lower 95% Confidence Limit .............. - 0.43 1.02 0.98 - Upper 95% Confidence Limit .............. - 1.21 1.48 0.99 - Risk-adjusted Rate ................................ - 37.1% 58.9% 46.4% 46.9% Long stay: PLOS >14 days Odds Ratio ............................................ - 0.87 0.88 0.88 1.00 Lower 95% Confidence Limit .............. - 0.37 0.47 0.80 - Upper 95% Confidence Limit .............. - 2.05 1.65 0.97 - O/E Ratio ............................................... - 0.56 0.76 0.99 1.00 Lower 95% Confidence Limit .............. - 0.03 0.32 0.96 - Upper 95% Confidence Limit .............. - 2.71 1.53 1.03 - Risk-adjusted Rate ................................ - 2.8% 3.8% 4.9% 5.0% 1 Refer to the Report Overview for information on risk-adjustment methodology Risk-adjustment is not performed on time periods of less than 6 months CABG -- 28

23. Isolated CABG Procedures Subset: On-pump procedures Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Number of On-Pump Procedures - 21 65 47,643 101,632 Demographics Age (years), median .............................. - 72.0 70.0 66.0 66.0 Gender, Female ..................................... - 9.5% 23.1% 24.1% 24.1% Race, Non-caucasian ............................ - 4.8% 3.1% 16.8% 17.2% Multiple Races ....................................... - 0.0% 3.1% 1.1% 0.9% Obesity (BMI 30.0+) .............................. - 38.1% 49.2% 45.1% 44.8% Comorbidities Diabetes Mellitus ................................... - 47.6% 44.6% 49.4% 49.4% Insulin-Dependent .............................. - 23.8% 26.2% 17.9% 18.2% Hypertension ......................................... - 81.0% 83.1% 89.2% 89.3% Dyslipidemia .......................................... - 81.0% 83.1% 89.4% 90.1% Current/Recent Cigarette Smoker ......... - 4.8% 23.1% 22.8% 22.1% Chronic Lung Disease, Mild+ ................. - 0.0% 27.7% 19.2% 17.8% Congestive Heart Failure ....................... - 4.8% 32.3% 17.9% 18.6% CHF / NYHA class IV1 ........................ - 0.0% 0.0% 4.3% 4.1% Peripheral Arterial Disease .................... - 0.0% 9.2% 13.6% 13.6% Cerebrovascular Disease ...................... - 9.5% 26.2% 21.5% 21.4% CVA .................................................... - 0.0% 6.2% 7.4% 7.7% Renal failure, Dialysis-Dependent ......... - 0.0% 3.1% 3.2% 3.1% Last Creatinine Preop >= 4.0 mg/dl ....... - 0.0% 1.5% 2.3% 2.5% Immunosuppressive Treatment ............. - 4.8% 0.0% 3.0% 3.2% Previous Interventions Previous Cardiac Surgery2 .................... - 0.0% 9.2% 2.1% 2.4% Previous CAB ..................................... - 0.0% 7.7% 1.5% 1.8% Previous PCI ......................................... - 9.5% 30.8% 30.4% 30.6% Status Surgery status, Emergent or Salvage .... - 28.6% 4.6% 4.7% 4.2% MI .......................................................... - 28.6% 41.5% 54.6% 54.3% <= 7 days Prior to Surgery ................. - 23.8% 23.1% 31.6% 30.2% Cardiogenic Shock ................................ - 19.0% 1.5% 1.6% 1.6% Resuscitation ......................................... - 0.0% 0.0% 0.3% 0.3% 1 NYHA Class is only collected for patients with CHF % represents proportion of cases that had both CHF and the indicated NYHA class 2 Previous cardiac surgery reflects any prior CABG, valve, or other cardiac surgery CABG On-pump procedures -- 29

24. Isolated CABG Procedures Subset: On-pump procedures Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Hemodynamics and Catheterization Triple Vessel Disease ............................ - 61.9% 78.5% 78.2% 78.1% Left Main Disease (>=50% stenosis) ..... - 38.1% 35.4% 32.5% 31.9% Ejection Fraction < 40%1 ....................... - 12.5% 25.0% 15.6% 15.5% Aortic Stenosis ...................................... - 0.0% 4.6% 3.5% 3.5% Mitral Insufficiency, Mild+ ...................... - 4.8% 33.8% 32.8% 32.8% Operative Information IABP, Preoperative ................................ - 28.6% 20.0% 7.6% 6.9% Cross-Clamp Time (min) Mean .................................................. - 75.6 - 71.1 69.2 Median ............................................... - 77.0 - 66.0 65.0 Cardiopulmonary Bypass Time (min) Mean .................................................. - 110.8 53.2 97.3 94.7 Median ............................................... - 111.0 49.0 92.0 89.0 Postoperative Information Ventilation hours, total Mean .................................................. - 36.9 11.1 17.7 17.3 Median ............................................... - 11.7 7.6 5.8 5.8 ICU hours, total Mean .................................................. - 143.7 149.6 78.9 73.3 Median ............................................... - 117.2 120.2 52.0 48.2 Mortality Summary & Risk-Adjustment2 In-hospital Mortality Observed rate ..................................... - 4.8% 0.0% 2.0% 1.8% Risk-adjusted rate .............................. - 3.2% 0.0% 1.6% 1.5% Operative Mortality Observed rate ..................................... - 4.8% 0.0% 2.6% 2.3% Risk-adjusted rate .............................. - 3.5% 0.0% 2.3% 2.1% 1 Among patients with measured EF 2 Refer to the Report Overview for information on risk-adjustment methodology Risk-adjustment is not performed on time periods of less than 6 months CABG On-pump procedures -- 30

25. Isolated CABG Procedures Subset: On-pump procedures Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Complications Summary & Risk-Adjustment1 Major Complications or Op. Mortality Observed Rate ................................... - 23.8% 13.8% 13.3% 12.3% Risk-adjusted Rate ............................. - 14.5% 8.9% 10.3% 9.7% Any Reoperation Observed Rate ................................... - 0.0% 4.6% 3.7% 3.8% Risk-adjusted Rate ............................. - 0.0% 3.5% 3.2% 3.2% Deep Sternal Infection/Mediastinitis Observed Rate ................................... - 0.0% 0.0% 0.3% 0.3% Risk-adjusted Rate ............................. - 0.0% 0.0% 0.3% 0.3% Permanent Stroke Observed Rate ................................... - 0.0% 0.0% 1.4% 1.4% Risk-adjusted Rate ............................. - 0.0% 0.0% 1.1% 1.1% Renal Failure2 Observed Rate ................................... - 0.0% 1.6% 2.5% 2.2% Risk-adjusted Rate ............................. - 0.0% 1.1% 2.0% 1.7% Prolonged Ventilation Observed Rate ................................... - 19.0% 10.8% 8.6% 7.8% Risk-adjusted Rate ............................. - 9.7% 5.7% 6.0% 5.6% Readmission3 Readmitted within 30 days4 ................... - 5.0% 18.5% 10.7% 10.1% Length of Stay Summary Total length of stay (days) Mean .................................................. - 9.6 9.3 9.4 9.4 Median ............................................... - 7.0 8.0 8.0 8.0 Post-procedure Length of Stay (days) Mean .................................................. - 8.0 7.2 7.0 7.0 1 Refer to the Report Overview for information on risk-adjustment methodology Median ............................................... - 7.0 6.0 6.0 6.0 Risk-adjustment is not performed on time periods of less than 6 months 2 Excludes patients with preoperative dialysis or last creatinine >=4 3 Excludes in-hospital mortalities 4 Timed from discharge for v2.81 CABG On-pump procedures -- 31

26. CABG On-pump procedures -- 32

27. Isolated CABG Procedures Subset: Off-pump procedures Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Number of Off-Pump Procedures - 11 51 7,232 14,582 Demographics Age (years), median .............................. - 78.0 71.0 66.0 66.0 Gender, Female ..................................... - 9.1% 29.4% 26.8% 27.1% Race, Non-caucasian ............................ - 9.1% 2.0% 15.7% 18.2% Multiple Races ....................................... - 0.0% 2.0% 1.3% 1.0% Obesity (BMI 30.0+) .............................. - 54.5% 37.3% 43.5% 43.2% Comorbidities Diabetes Mellitus ................................... - 45.5% 60.8% 49.1% 49.0% Insulin-Dependent .............................. - 27.3% 45.1% 18.5% 18.6% Hypertension ......................................... - 54.5% 94.1% 90.7% 90.2% Dyslipidemia .......................................... - 54.5% 74.5% 91.1% 91.1% Current/Recent Cigarette Smoker ......... - 18.2% 19.6% 21.4% 21.4% Chronic Lung Disease, Mild+ ................. - 18.2% 35.3% 21.0% 20.0% Congestive Heart Failure ....................... - 0.0% 41.2% 16.7% 17.4% CHF / NYHA class IV1 ........................ - 0.0% 2.0% 3.5% 3.5% Peripheral Arterial Disease .................... - 9.1% 23.5% 15.3% 16.1% Cerebrovascular Disease ...................... - 27.3% 27.5% 22.8% 23.0% CVA .................................................... - 0.0% 7.8% 9.1% 9.1% Renal failure, Dialysis-Dependent ......... - 0.0% 3.9% 3.7% 3.6% Last Creatinine Preop >= 4.0 mg/dl ....... - 0.0% 2.0% 3.1% 3.1% Immunosuppressive Treatment ............. - 0.0% 0.0% 3.9% 3.7% Previous Interventions Previous Cardiac Surgery2 .................... - 0.0% 3.9% 2.6% 2.7% Previous CAB ..................................... - 0.0% 2.0% 1.7% 1.7% Previous PCI ......................................... - 27.3% 31.4% 32.6% 33.0% Status Surgery status, Emergent or Salvage .... - 9.1% 2.0% 4.1% 3.6% MI .......................................................... - 18.2% 43.1% 53.2% 51.9% <= 7 days Prior to Surgery ................. - 18.2% 23.5% 29.5% 27.0% Cardiogenic Shock ................................ - 9.1% 0.0% 1.0% 1.0% Resuscitation ......................................... - 0.0% 0.0% 0.1% 0.1% 1 NYHA Class is only collected for patients with CHF % represents proportion of cases that had both CHF and the indicated NYHA class 2 Previous cardiac surgery reflects any prior CABG, valve, or other cardiac surgery CABG Off-pump procedures -- 33

28. Isolated CABG Procedures Subset: Off-pump procedures Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Hemodynamics and Catheterization Triple Vessel Disease ............................ - 63.6% 68.6% 65.0% 63.9% Left Main Disease (>=50% stenosis) ..... - 54.5% 29.4% 30.3% 28.9% Ejection Fraction < 40%1 ....................... - 0.0% 27.7% 14.9% 14.3% Aortic Stenosis ...................................... - 0.0% 5.9% 4.0% 4.1% Mitral Insufficiency, Mild+ ...................... - 9.1% 43.1% 31.8% 31.1% Operative Information IABP, Preoperative ................................ - 0.0% 9.8% 6.1% 5.6% Cross-Clamp Time (min) Mean .................................................. -- -- -- -- -- Median ............................................... -- -- -- -- -- Cardiopulmonary Bypass Time (min) Mean .................................................. -- -- -- -- -- Median ............................................... -- -- -- -- -- Postoperative Information Ventilation hours, total Mean .................................................. - 12.4 6.3 12.7 13.2 Median ............................................... - 8.1 3.7 4.7 4.9 ICU hours, total Mean .................................................. - 117.9 133.0 71.6 65.1 Median ............................................... - 120.5 122.4 49.4 46.0 Mortality Summary & Risk-Adjustment2 In-hospital Mortality Observed rate ..................................... - 0.0% 2.0% 1.6% 1.5% Risk-adjusted rate .............................. - 0.0% 1.7% 1.6% 1.5% Operative Mortality Observed rate ..................................... - 0.0% 3.9% 2.3% 2.1% Risk-adjusted rate .............................. - 0.0% 3.3% 2.2% 2.1% 1 Among patients with measured EF 2 Refer to the Report Overview for information on risk-adjustment methodology Risk-adjustment is not performed on time periods of less than 6 months CABG Off-pump procedures -- 34

29. Isolated CABG Procedures Subset: Off-pump procedures Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Complications Summary & Risk-Adjustment1 Major Complications or Op. Mortality Observed Rate ................................... - 18.2% 11.8% 9.9% 9.4% Risk-adjusted Rate ............................. - 17.7% 9.7% 10.1% 9.8% Any Reoperation Observed Rate ................................... - 0.0% 0.0% 2.9% 3.1% Risk-adjusted Rate ............................. - 0.0% 0.0% 2.9% 3.2% Deep Sternal Infection/Mediastinitis Observed Rate ................................... - 0.0% 0.0% 0.2% 0.3% Risk-adjusted Rate ............................. - 0.0% 0.0% 0.2% 0.3% Permanent Stroke Observed Rate ................................... - 0.0% 0.0% 1.0% 1.0% Risk-adjusted Rate ............................. - 0.0% 0.0% 1.0% 1.1% Renal Failure2 Observed Rate ................................... - 0.0% 0.0% 2.0% 1.7% Risk-adjusted Rate ............................. - 0.0% 0.0% 2.0% 1.8% Prolonged Ventilation Observed Rate ................................... - 18.2% 9.8% 5.9% 5.4% Risk-adjusted Rate ............................. - 20.1% 8.1% 6.1% 5.7% Readmission3 Readmitted within 30 days4 ................... - 36.4% 12.0% 10.5% 10.0% Length of Stay Summary Total length of stay (days) Mean .................................................. - 7.4 9.1 8.8 8.6 Median ............................................... - 7.0 9.0 7.0 7.0 Post-procedure Length of Stay (days) Mean .................................................. - 5.5 6.4 6.4 6.3 1 Refer to the Report Overview for information on risk-adjustment methodology Median ............................................... - 5.0 6.0 5.0 5.0 Risk-adjustment is not performed on time periods of less than 6 months 2 Excludes patients with preoperative dialysis or last creatinine >=4 3 Excludes in-hospital mortalities 4 Timed from discharge for v2.81 CABG Off-pump procedures -- 35

30. CABG Off-pump procedures -- 36

31. Isolated CABG Procedures Subset: First Operations Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Number of First Operations - 32 108 53,693 113,315 Demographics Age (years), median .............................. - 72.5 70.0 66.0 66.0 Gender, Female ..................................... - 9.4% 26.9% 24.5% 24.5% Race, Non-caucasian ............................ - 6.3% 2.8% 16.8% 17.4% Multiple Races ....................................... - 0.0% 2.8% 1.2% 1.0% Obesity (BMI 30.0+) .............................. - 43.8% 44.4% 44.9% 44.6% Comorbidities Diabetes Mellitus ................................... - 46.9% 50.9% 49.3% 49.3% Insulin-Dependent .............................. - 25.0% 33.3% 18.0% 18.2% Hypertension ......................................... - 71.9% 88.9% 89.3% 89.2% Dyslipidemia .......................................... - 71.9% 79.6% 89.5% 90.0% Current/Recent Cigarette Smoker ......... - 9.4% 23.1% 22.7% 22.1% Chronic Lung Disease, Mild+ ................. - 6.3% 29.6% 19.3% 17.9% Congestive Heart Failure ....................... - 3.1% 37.0% 17.7% 18.4% CHF / NYHA class IV1 ........................ - 0.0% 0.9% 4.2% 4.1% Peripheral Arterial Disease .................... - 3.1% 15.7% 13.6% 13.7% Cerebrovascular Disease ...................... - 15.6% 25.0% 21.5% 21.4% CVA .................................................... - 0.0% 5.6% 7.6% 7.8% Renal failure, Dialysis-Dependent ......... - 0.0% 3.7% 3.2% 3.2% Last Creatinine Preop >= 4.0 mg/dl ....... - 0.0% 1.9% 2.4% 2.5% Immunosuppressive Treatment ............. - 3.1% 0.0% 3.1% 3.3% Previous Interventions Previous Cardiac Surgery2 .................... - 0.0% 0.0% 0.0% 0.0% Previous CAB ..................................... - 0.0% 0.0% 0.0% 0.0% Previous PCI ......................................... - 15.6% 26.9% 30.1% 30.1% Status Surgery status, Emergent or Salvage .... - 21.9% 2.8% 4.6% 4.1% MI .......................................................... - 25.0% 40.7% 54.3% 53.8% <= 7 days Prior to Surgery ................. - 21.9% 22.2% 31.6% 30.1% Cardiogenic Shock ................................ - 15.6% 0.9% 1.5% 1.5% Resuscitation ......................................... - 0.0% 0.0% 0.3% 0.3% 1 NYHA Class is only collected for patients with CHF % represents proportion of cases that had both CHF and the indicated NYHA class 2 Previous cardiac surgery reflects any prior CABG, valve, or other cardiac surgery CABG First Operations -- 37

32. Isolated CABG Procedures Subset: First Operations Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Hemodynamics and Catheterization Triple Vessel Disease ............................ - 62.5% 74.1% 76.4% 76.2% Left Main Disease (>=50% stenosis) ..... - 43.8% 31.5% 31.9% 31.3% Ejection Fraction < 40%1 ....................... - 8.0% 26.3% 15.4% 15.3% Aortic Stenosis ...................................... - 0.0% 5.6% 3.5% 3.5% Mitral Insufficiency, Mild+ ...................... - 6.3% 38.0% 32.6% 32.4% Operative Information IABP, Preoperative ................................ - 18.8% 14.8% 7.4% 6.7% Cross-Clamp Time (min) Mean .................................................. - 75.6 - 71.0 69.1 Median ............................................... - 77.0 - 66.0 65.0 Cardiopulmonary Bypass Time (min) Mean .................................................. - 110.8 51.5 96.9 94.3 Median ............................................... - 111.0 48.0 91.0 89.0 Postoperative Information Ventilation hours, total Mean .................................................. - 28.2 9.1 16.8 16.5 Median ............................................... - 8.7 5.3 5.7 5.6 ICU hours, total Mean .................................................. - 134.8 142.6 77.6 71.9 Median ............................................... - 120.3 121.2 51.6 48.0 Mortality Summary & Risk-Adjustment2 In-hospital Mortality Observed rate ..................................... - 3.1% 0.9% 1.8% 1.7% Risk-adjusted rate .............................. - 2.6% 0.7% 1.8% 1.6% Operative Mortality Observed rate ..................................... - 3.1% 1.9% 2.5% 2.2% Risk-adjusted rate .............................. - 2.6% 1.5% 2.4% 2.2% 1 Among patients with measured EF 2 Refer to the Report Overview for information on risk-adjustment methodology Risk-adjustment is not performed on time periods of less than 6 months CABG First Operations -- 38

33. Isolated CABG Procedures Subset: First Operations Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Complications Summary & Risk-Adjustment1 Major Complications or Op. Mortality Observed Rate ................................... - 21.9% 13.9% 12.7% 11.8% Risk-adjusted Rate ............................. - 18.0% 11.3% 12.4% 11.7% Any Reoperation Observed Rate ................................... - 0.0% 2.8% 3.5% 3.6% Risk-adjusted Rate ............................. - 0.0% 2.5% 3.5% 3.6% Deep Sternal Infection/Mediastinitis Observed Rate ................................... - 0.0% 0.0% 0.3% 0.3% Risk-adjusted Rate ............................. - 0.0% 0.0% 0.3% 0.3% Permanent Stroke Observed Rate ................................... - 0.0% 0.0% 1.4% 1.4% Risk-adjusted Rate ............................. - 0.0% 0.0% 1.4% 1.3% Renal Failure2 Observed Rate ................................... - 0.0% 1.0% 2.4% 2.1% Risk-adjusted Rate ............................. - 0.0% 1.0% 2.3% 2.1% Prolonged Ventilation Observed Rate ................................... - 18.8% 11.1% 8.1% 7.3% Risk-adjusted Rate ............................. - 14.9% 8.6% 7.9% 7.3% Readmission3 Readmitted within 30 days4 ................... - 16.1% 15.0% 10.6% 10.0% Length of Stay Summary Total length of stay (days) Mean .................................................. - 8.8 9.2 9.3 9.3 Median ............................................... - 7.0 8.0 8.0 8.0 Post-procedure Length of Stay (days) Mean .................................................. - 7.1 6.9 6.9 6.9 1 Refer to the Report Overview for information on risk-adjustment methodology Median ............................................... - 6.0 6.0 6.0 6.0 Risk-adjustment is not performed on time periods of less than 6 months 2 Excludes patients with preoperative dialysis or last creatinine >=4 3 Excludes in-hospital mortalities 4 Timed from discharge for v2.81 CABG First Operations -- 39

34. CABG First Operations -- 40

35. Isolated CABG Procedures Subset: Reoperations Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Number of Reoperations - - 8 1,186 2,844 Demographics Age (years), median .............................. - - 74.0 69.0 69.0 Gender, Female ..................................... - - 12.5% 23.6% 22.0% Race, Non-caucasian ............................ - - 0.0% 12.2% 13.7% Multiple Races ....................................... - - 0.0% 0.9% 0.7% Obesity (BMI 30.0+) .............................. - - 37.5% 43.8% 44.4% Comorbidities Diabetes Mellitus ................................... - - 62.5% 51.4% 49.8% Insulin-Dependent .............................. - - 50.0% 18.0% 19.8% Hypertension ......................................... - - 75.0% 94.8% 95.1% Dyslipidemia .......................................... - - 75.0% 95.3% 96.3% Current/Recent Cigarette Smoker ......... - - 0.0% 16.4% 16.6% Chronic Lung Disease, Mild+ ................. - - 50.0% 24.7% 22.8% Congestive Heart Failure ....................... - - 25.0% 18.0% 19.2% CHF / NYHA class IV1 ........................ - - 0.0% 3.3% 3.8% Peripheral Arterial Disease .................... - - 12.5% 24.5% 24.2% Cerebrovascular Disease ...................... - - 50.0% 28.7% 29.3% CVA .................................................... - - 25.0% 8.4% 9.7% Renal failure, Dialysis-Dependent ......... - - 0.0% 2.9% 2.9% Last Creatinine Preop >= 4.0 mg/dl ....... - - 0.0% 2.0% 2.4% Immunosuppressive Treatment ............. - - 0.0% 3.9% 3.7% Previous Interventions Previous Cardiac Surgery2 .................... - - 100.0% 100.0% 100.0% Previous CAB ..................................... - - 75.0% 72.3% 73.9% Previous PCI ......................................... - - 87.5% 59.0% 59.6% Status Surgery status, Emergent or Salvage .... - - 12.5% 3.8% 3.0% MI .......................................................... - - 62.5% 60.8% 61.0% <= 7 days Prior to Surgery ................. - - 37.5% 19.6% 19.3% Cardiogenic Shock ................................ - - 0.0% 2.1% 1.8% Resuscitation ......................................... - - 0.0% 0.6% 0.4% 1 NYHA Class is only collected for patients with CHF % represents proportion of cases that had both CHF and the indicated NYHA class 2 Previous cardiac surgery reflects any prior CABG, valve, or other cardiac surgery CABG Reoperations -- 41

36. Isolated CABG Procedures Subset: Reoperations Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Hemodynamics and Catheterization Triple Vessel Disease ............................ - - 75.0% 78.4% 79.5% Left Main Disease (>=50% stenosis) ..... - - 50.0% 42.5% 40.1% Ejection Fraction < 40%1 ....................... - - 25.0% 17.4% 16.4% Aortic Stenosis ...................................... - - 0.0% 5.6% 5.5% Mitral Insufficiency, Mild+ ...................... - - 37.5% 38.6% 39.3% Operative Information IABP, Preoperative ................................ - - 25.0% 6.0% 5.7% Cross-Clamp Time (min) Mean .................................................. - - - 75.5 73.2 Median ............................................... - - - 68.0 68.0 Cardiopulmonary Bypass Time (min) Mean .................................................. - - 70.5 115.7 112.4 Median ............................................... - - 68.0 108.0 104.0 Postoperative Information Ventilation hours, total Mean .................................................. - - 7.7 28.4 28.6 Median ............................................... - - 6.9 6.9 6.6 ICU hours, total Mean .................................................. - - 138.1 92.0 87.0 Median ............................................... - - 140.8 63.0 52.0 Mortality Summary & Risk-Adjustment2 In-hospital Mortality Observed rate ..................................... - - 0.0% 5.5% 4.7% Risk-adjusted rate .............................. - - 0.0% 6.9% 6.1% Operative Mortality Observed rate ..................................... - - 0.0% 6.7% 5.8% Risk-adjusted rate .............................. - - 0.0% 7.7% 6.8% 1 Among patients with measured EF 2 Refer to the Report Overview for information on risk-adjustment methodology Risk-adjustment is not performed on time periods of less than 6 months CABG Reoperations -- 42

37. Isolated CABG Procedures Subset: Reoperations Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Complications Summary & Risk-Adjustment1 Major Complications or Op. Mortality Observed Rate ................................... - - 0.0% 19.9% 19.8% Risk-adjusted Rate ............................. - - 0.0% 23.1% 22.9% Any Reoperation Observed Rate ................................... - - 0.0% 6.2% 6.9% Risk-adjusted Rate ............................. - - 0.0% 8.0% 8.9% Deep Sternal Infection/Mediastinitis Observed Rate ................................... - - 0.0% 0.5% 0.4% Risk-adjusted Rate ............................. - - 0.0% 0.5% 0.4% Permanent Stroke Observed Rate ................................... - - 0.0% 1.9% 2.1% Risk-adjusted Rate ............................. - - 0.0% 2.6% 2.8% Renal Failure2 Observed Rate ................................... - - 0.0% 4.9% 4.0% Risk-adjusted Rate ............................. - - 0.0% 5.7% 4.5% Prolonged Ventilation Observed Rate ................................... - - 0.0% 12.7% 13.4% Risk-adjusted Rate ............................. - - 0.0% 15.4% 16.2% Readmission3 Readmitted within 30 days4 ................... - - 25.0% 13.4% 12.0% Length of Stay Summary Total length of stay (days) Mean .................................................. - - 9.5 10.5 10.5 Median ............................................... - - 9.5 9.0 9.0 Post-procedure Length of Stay (days) Mean .................................................. - - 6.0 7.7 7.7 1 Refer to the Report Overview for information on risk-adjustment methodology Median ............................................... - - 5.5 6.0 6.0 Risk-adjustment is not performed on time periods of less than 6 months 2 Excludes patients with preoperative dialysis or last creatinine >=4 3 Excludes in-hospital mortalities 4 Timed from discharge for v2.81 CABG Reoperations -- 43

38. CABG Reoperations -- 44

39. Isolated Aortic Valve Replacement Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Number of Cases - 1 17 3,665 18,759 Demographics Age (years) Mean ..................................................... - 75.0 70.2 65.9 65.5 Median ................................................... - 75.0 75.0 68.0 67.0 25th Percentile ....................................... - 75.0 64.0 60.0 59.0 75th Percentile ....................................... - 75.0 79.0 74.0 74.0 Age >= 65 years old .............................. - 100.0% 70.6% 60.0% 59.7% Gender, Female ........................................ - 0.0% 29.4% 39.8% 36.9% Missing .................................................. - 0.0% 0.0% 0.1% 0.0% Race1 Caucasian ............................................. - 100.0% 100.0% 85.9% 86.9% Black ...................................................... - 0.0% 0.0% 6.1% 5.6% Asian ..................................................... - 0.0% 0.0% 1.4% 1.5% Native American .................................... - 0.0% 0.0% 0.6% 0.5% Native Hawaiian/Pacific Islander ........... - 0.0% 0.0% 0.4% 0.2% Other ..................................................... - 0.0% 0.0% 3.7% 3.0% Multiple Races ....................................... - 0.0% 0.0% 1.1% 0.6% Missing / Not Documented .................... - 0.0% 0.0% 2.9% 3.0% Pt. Declined to Disclose2 ....................... - 0.0% 0.0% 0.4% 0.6% Hispanic or Latino Ethnicity ...................... - 0.0% 41.2% 11.1% 7.2% Missing/ Not Documented ..................... - 0.0% 5.9% 4.0% 3.9% Body Mass Index3 Underweight (BMI < 18.5) ...................... - 0.0% 0.0% 0.9% 0.9% Normal (BMI 18.5 - 24.9) ....................... - 0.0% 23.5% 18.9% 19.0% Overweight (BMI 25.0 - 29.9) ................ - 100.0% 35.3% 31.4% 32.9% Obese I (BMI 30.0 - 34.9) ...................... - 0.0% 23.5% 26.2% 25.8% Obese II (BMI 35.0 - 39.9) ..................... - 0.0% 11.8% 13.2% 12.9% Morbid Obesity (BMI 40.0+) ................... - 0.0% 5.9% 9.2% 8.3% Missing Height ....................................... - 0.0% 0.0% 0.1% 0.2% 1 Data presented in the report represent the individual response rates for each race category Missing Weight ...................................... - 0.0% 0.0% 0.0% 0.2% shown; summing the individual non-caucasian categories will not result in the same rates as shown in the graph since non-caucasian, as defined for the graph, does not include races or ethnicities reported in combination with caucasian 2 Option added in v2.81 3 BMI = Weight(kg) / Height(m)2 AV Replace -- 45

40. Isolated Aortic Valve Replacement Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Comorbidities Diabetes Mellitus ...................................... - 0.0% 23.5% 34.2% 30.4% Diet Control ........................................ - 0.0% 0.0% 2.2% 2.7% Oral Control ........................................ - 0.0% 17.6% 18.3% 16.2% Insulin Control .................................... - 0.0% 5.9% 9.7% 7.9% Other SQ Medication Control1 ............ - 0.0% 0.0% 0.3% 0.3% Other Control ...................................... - 0.0% 0.0% 0.2% 0.1% Missing Control ................................... - - 0.0% 1.0% 0.8% Missing .................................................. - 0.0% 0.0% 0.3% 0.4% Hypertension ............................................ - 0.0% 70.6% 81.0% 78.8% Missing .................................................. - 0.0% 5.9% 0.3% 0.3% Current/Recent Cigarette Smoker ............ - 0.0% 23.5% 16.1% 13.3% Smoker, Current Status Unknown1 ........ - 0.0% 5.9% 0.4% 0.4% Missing .................................................. - 0.0% 0.0% 0.8% 0.7% Chronic Lung Disease Mild ........................................................ - 0.0% 17.6% 10.2% 9.4% Moderate ............................................... - 0.0% 17.6% 4.6% 3.9% Severe ................................................... - 0.0% 0.0% 4.6% 3.4% Unknown Severity1 ................................ - 0.0% 29.4% 6.2% 5.6% Missing .................................................. - 0.0% 23.5% 3.1% 1.8% Congestive Heart Failure .......................... - 0.0% 64.7% 28.2% 33.8% CHF / NYHA Class I2 .......................... - 0.0% 23.5% 1.9% 3.1% CHF / NYHA Class II .......................... - 0.0% 5.9% 9.4% 13.6% CHF / NYHA Class III ......................... - 0.0% 17.6% 14.1% 17.0% CHF / NYHA Class IV ......................... - 0.0% 11.8% 5.8% 5.0% CHF / Missing Class ........................... - - 0.0% 2.2% 2.0% Missing .................................................. - 0.0% 17.6% 1.5% 1.2% Peripheral Arterial Disease ....................... - 0.0% 11.8% 7.9% 7.6% Missing .................................................. - 0.0% 0.0% 1.2% 0.5% Cerebrovascular Disease ......................... - 0.0% 23.5% 15.0% 15.2% 1 Option added in v2.81 Missing .................................................. - 0.0% 0.0% 1.2% 0.9% 2 NYHA Class is only collected for patients with CHF % represents proportion of cases that had both CHF and the indicated NYHA class Coma/Nonresponsive State ................... - 0.0% 0.0% 0.3% 0.3% Missing ............................................... - 0.0% 0.0% 0.9% 1.4% AV Replace -- 46

41. Isolated Aortic Valve Replacement Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 CVD TIA ................................................ - 0.0% 0.0% 3.9% 4.0% Missing ............................................... - 0.0% 11.8% 1.6% 1.1% Carotid Stenosis1 None ................................................... - 100.0% 82.4% 92.6% 93.0% 50-79%2 .............................................. - 0.0% 11.8% 4.5% 4.6% 80-100% ............................................. - 0.0% 0.0% 0.7% 0.6% Missing/Not Documented ................... - 0.0% 5.9% 2.3% 1.7% CVD Prior Carotid Surgery .................... - 0.0% 11.8% 1.5% 1.5% Missing ............................................... - 0.0% 0.0% 1.3% 0.9% Cerebrovascular Accident ..................... - 0.0% 5.9% 6.7% 6.9% Missing ............................................... - 0.0% 5.9% 1.3% 0.9% Renal Failure, Dialysis-Dependent ........... - 0.0% 0.0% 3.1% 2.1% Missing .................................................. - 0.0% 5.9% 0.4% 0.4% Last Creatinine Preop Mean ..................................................... - 1.0 1.0 1.1 1.1 Median ................................................... - 1.0 1.0 1.0 0.9 25th Percentile ....................................... - 1.0 0.9 0.8 0.8 75th Percentile ....................................... - 1.0 1.2 1.2 1.1 Missing .................................................. - 0.0% 0.0% 0.3% 0.4% Value >= 4.0 mg/dL ............................... - 0.0% 0.0% 1.9% 1.5% Immunosuppressive Treatment ................ - 0.0% 5.9% 3.6% 4.1% Missing .................................................. - 0.0% 0.0% 1.2% 0.8% Infectious Endocarditis .............................. - 0.0% 0.0% 6.8% 7.3% Missing .................................................. - 0.0% 0.0% 0.1% 0.3% Previous Interventions Previous Cardiac Surgery3 ....................... - 0.0% 17.6% 7.3% 10.7% First reoperation .................................... - 0.0% 17.6% 6.9% 9.8% 1 Defined as highest level of occlusion in either carotid. Previous CABG ........................................ - 0.0% 11.8% 2.2% 2.8% 2 Option added in v2.81 3 Previous cardiac surgery reflects any prior CABG, valve, or other cardiac surgery Previous Valve .......................................... - 0.0% 5.9% 5.2% 7.8% Previous AICD .......................................... - 0.0% 5.9% 1.1% 1.0% AV Replace -- 47

42. Isolated Aortic Valve Replacement Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Previous Pacemaker ................................. - 0.0% 0.0% 2.6% 2.8% Status Surgery Status Elective .................................................. - 0.0% 58.8% 77.9% 80.7% Urgent .................................................... - 100.0% 41.2% 21.4% 18.4% Emergent ............................................... - 0.0% 0.0% 0.6% 0.7% Emergent Salvage ................................. - 0.0% 0.0% 0.1% 0.1% Missing .................................................. - 0.0% 0.0% 0.0% 0.1% MI .............................................................. - 0.0% 0.0% 10.3% 9.6% Missing .................................................. - 0.0% 23.5% 0.8% 0.6% Cardiogenic Shock At the time of surgery ............................ - 0.0% 5.9% 0.5% 0.7% Within 24 hrs of surgery1 ....................... - 0.0% 0.0% 0.2% 0.2% Missing .................................................. - 0.0% 0.0% 0.2% 0.3% Hemodynamics and Catheterization Ejection Fraction Mean ..................................................... - 60.0 54.8 57.2 57.7 Median ................................................... - 60.0 55.0 60.0 60.0 25th Percentile ....................................... - 60.0 50.0 55.0 55.0 75th Percentile ....................................... - 60.0 65.0 63.0 65.0 EF missing or not measured .................. - 0.0% 11.8% 4.3% 2.8% EF <40%2 .............................................. - 0.0% 13.3% 7.6% 7.1% Pulmonary Hypertension3 ......................... - - 70.0% 48.7% 45.5% PA mean/systolic pressure missing or not measured .................................... - 100.0% 41.2% 47.9% 46.5% Aortic Stenosis .......................................... - 100.0% 94.1% 84.2% 82.7% Missing .................................................. - 0.0% 0.0% 0.1% 0.1% Aortic Insufficiency 1 Option added in v2.81 Trivial ..................................................... - 0.0% 0.0% 11.2% 14.4% 2 Among patients with measured EF Mild ........................................................ - 0.0% 5.9% 22.8% 24.1% 3 PA systolic pressure > 35mmHg Moderate ............................................... - 0.0% 0.0% 14.1% 15.2% Severe ................................................... - 100.0% 94.1% 24.6% 21.9% Missing/Not Documented ...................... - 0.0% 0.0% 6.7% 4.9% AV Replace -- 48

43. Isolated Aortic Valve Replacement Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Preoperative Medications Aspirin ....................................................... - 0.0% 47.1% 54.4% 49.2% Among Eligible Cases ........................... - 0.0% 47.1% 54.9% 49.7% Contraindicated / Not Indicated ............. - 0.0% 0.0% 1.0% 1.1% Missing .................................................. - 0.0% 5.9% 1.1% 0.8% Inotropics .................................................. - 0.0% 5.9% 1.0% 1.1% Missing .................................................. - 0.0% 0.0% 0.3% 0.2% Beta Blockers ........................................... - 0.0% 23.5% 64.2% 60.2% Among Eligible Cases ........................... - 0.0% 25.0% 68.1% 64.3% Contraindicated / Not Indicated ............. - 0.0% 5.9% 5.6% 6.2% Missing .................................................. - 0.0% 0.0% 0.0% 0.2% Steroids .................................................... - 0.0% 5.9% 2.4% 2.1% Among Eligible Cases ........................... - 0.0% 5.9% 2.4% 2.1% Contraindicated / Not Indicated ............. - 0.0% 0.0% 0.0% 0.0% Missing .................................................. - 0.0% 0.0% 0.5% 0.4% Nitrates IV ................................................. - 0.0% 5.9% 0.6% 0.4% Missing .................................................. - 0.0% 0.0% 0.5% 0.4% ACE Inhibitors ........................................... - 0.0% 5.9% 36.5% 33.5% Among Eligible Cases ........................... - 0.0% 6.3% 37.2% 34.0% Contraindicated / Not Indicated ............. - 0.0% 5.9% 1.8% 1.3% Missing .................................................. - 0.0% 0.0% 1.3% 0.9% Anticoagulants .......................................... - 0.0% 29.4% 13.0% 11.4% Missing .................................................. - 0.0% 0.0% 0.5% 0.4% Coumadin1 ................................................ - 0.0% 0.0% 0.7% 0.4% Missing .................................................. - 0.0% 0.0% 0.7% 0.5% Coumadin w/in 5 Days 2 ........................... - - 0.0% 0.9% 0.8% Among Eligible Cases ........................... - - 0.0% 0.9% 0.8% Contraindicated / Not Indicated ............. - - 0.0% 0.2% 0.2% 1 Variable dropped in v2.9 Missing .................................................. - - 0.0% 0.6% 0.5% 2 Variable added in v2.9 AV Replace -- 49

44. Isolated Aortic Valve Replacement Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Lipid-Lowering agents ............................... - 0.0% 23.5% 55.4% 53.6% Among Eligible Cases ........................... - 0.0% 23.5% 56.0% 54.1% Contraindicated / Not Indicated ............. - 0.0% 0.0% 1.1% 0.9% Missing .................................................. - 0.0% 0.0% 1.1% 0.8% Glycoprotein IIb/IIIa Inhibitor ..................... - 0.0% 0.0% 0.1% 0.1% Missing .................................................. - 0.0% 0.0% 0.4% 0.3% ADP Inhibitors within 5 Days .................... - 0.0% 0.0% 1.4% 1.5% Among Eligible Cases ........................... - 0.0% 0.0% 1.4% 1.5% Contraindicated / Not Indicated ............. - 0.0% 0.0% 0.1% 0.2% Missing .................................................. - 0.0% 0.0% 0.4% 0.4% ADP Inhibitor Discontinuation1 < 1 Day ............................................... - - - 11.8% 21.2% 1 Day .................................................. - - - 19.6% 19.4% 2 Days ................................................ - - - 17.6% 10.1% 3 Days ................................................ - - - 15.7% 10.4% 4 Days ................................................ - - - 11.8% 18.8% 5 Days ................................................ - - - 19.6% 19.4% Missing .................................................. - - - 3.9% 0.7% Antiplatelets within 5 Days2 ...................... - 0.0% 0.0% 1.8% 1.4% Among Eligible Cases ........................... - 0.0% 0.0% 1.8% 1.4% Contraindicated / Not Indicated ............. - 0.0% 0.0% 0.1% 0.2% Missing .................................................. - 0.0% 0.0% 0.6% 0.5% Operative Information Blood Products Used ................................ - 100.0% 70.6% 31.1% 26.3% Number of Blood Product Units Used 1 Red Blood Cell Unit ......................... - 0.0% 5.9% 6.3% 5.9% 2 Red Blood Cell Units ....................... - 0.0% 11.8% 8.7% 6.4% 3 Red Blood Cell Units ....................... - 0.0% 11.8% 3.0% 2.0% 4+ Red Blood Cell Units ..................... - 100.0% 17.6% 2.9% 2.4% 1+ Fresh Frozen Plasma Units ........... - 0.0% 58.8% 11.7% 9.6% 1+ Cryoprecipitate Units ..................... - 100.0% 47.1% 4.8% 4.9% 1 Excludes patients not on ADP Inhibitors within 5 Days 1+ Platelet Units ................................. - 100.0% 52.9% 17.4% 15.3% 2 Variable dropped in v2.9 Missing .................................................. - 0.0% 0.0% 0.5% 0.6% AV Replace -- 50

45. Isolated Aortic Valve Replacement Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 IABP ......................................................... - 0.0% 29.4% 1.9% 1.7% Preop .................................................. - 0.0% 23.5% 0.3% 0.2% Intraop ................................................ - 0.0% 5.9% 1.3% 1.2% Postop ................................................ - 0.0% 0.0% 0.3% 0.2% Missing timing ..................................... - - 0.0% 0.0% 0.3% Missing .................................................. - 0.0% 0.0% 0.1% 0.1% Robotic Technology Assisted ................... - 0.0% 5.9% 0.1% 0.0% Missing .................................................. - 0.0% 0.0% 0.1% 0.9% Cross-Clamp Time (min) Mean ..................................................... - 89.0 75.0 80.8 74.8 Median ................................................... - 89.0 69.0 75.0 70.0 25th Percentile ....................................... - 89.0 65.0 61.0 55.0 75th Percentile ....................................... - 89.0 80.0 95.0 88.0 Cardiopulmonary Bypass Time (min) Mean ..................................................... - 114.0 117.4 108.8 100.8 Median ................................................... - 114.0 98.0 101.0 93.0 25th Percentile ....................................... - 114.0 89.0 81.0 74.0 75th Percentile ....................................... - 114.0 124.0 126.0 118.0 Circulatory Arrest ...................................... - 0.0% 0.0% 0.8% 0.4% Missing .................................................. - 0.0% 0.0% 0.2% 0.3% Circulatory Arrest Time (min) Mean ..................................................... - - - 17.8 18.0 Median ................................................... - - - 7.0 9.0 25th Percentile ....................................... - - - 3.0 1.0 75th Percentile ....................................... - - - 30.0 20.0 Skin Incision Duration (min) Mean ..................................................... - 234.0 259.4 216.5 204.2 Median ................................................... - 234.0 221.0 204.0 191.0 25th Percentile ....................................... - 234.0 200.0 170.0 157.0 75th Percentile ....................................... - 234.0 302.0 247.0 236.0 AV Replace -- 51

46. Isolated Aortic Valve Replacement Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 OR Duration (min) Mean ..................................................... - 331.0 350.2 300.5 290.1 Median ................................................... - 331.0 318.0 289.0 277.0 25th Percentile ....................................... - 331.0 290.0 246.0 234.0 75th Percentile ....................................... - 331.0 382.0 340.0 330.0 Valve Surgery Aortic Annular Enlargement ...................... - 0.0% 5.9% 4.0% 4.4% Missing .................................................. - 0.0% 0.0% 0.4% 0.9% Valve Replacement Type Mechanical ............................................ - 0.0% 5.9% 11.8% 11.3% Bioprosthetic .......................................... - 100.0% 94.1% 87.9% 88.3% Homograft .............................................. - 0.0% 0.0% 0.0% 0.1% Autograft ................................................ - - - - - Missing .................................................. - 0.0% 0.0% 0.2% 0.4% Antibiotic Selection1, 2 ............................... - 100.0% 100.0% 99.2% 99.4% Exclusions ............................................. - 0.0% 0.0% 1.8% 1.6% Missing .................................................. - 0.0% 0.0% 0.0% 0.1% Antibiotic Timing1, 3 ................................... - 100.0% 100.0% 99.1% 99.0% Exclusions ............................................. - 0.0% 0.0% 1.2% 1.1% Missing .................................................. - 0.0% 0.0% 0.0% 0.1% Antibiotics Discontinued1, 4 ........................ - 100.0% 100.0% 99.1% 99.2% Exclusions ............................................. - 0.0% 0.0% 3.0% 2.8% Missing .................................................. - 0.0% 0.0% 0.1% 0.2% Postoperative Information Blood Products Used ................................ - 100.0% 52.9% 33.1% 27.7% Number of Blood Product Units Used 1 Red Blood Cell Unit ......................... - 0.0% 11.8% 9.2% 8.7% 2 Red Blood Cell Units ....................... - 0.0% 23.5% 10.0% 7.6% 3 Red Blood Cell Units ....................... - 0.0% 0.0% 3.0% 2.8% 4+ Red Blood Cell Units ..................... - 100.0% 17.6% 6.6% 5.1% 1 All antibiotic measures are calculated among patients without exclusions 1+ Fresh Frozen Plasma Units ........... - 0.0% 11.8% 10.3% 8.2% 2 First or second generation cephalosporin prescribed/given prophylactically 1+ Cryoprecipitate Units ..................... - 100.0% 11.8% 5.1% 5.1% 3 Appropriate timing of prophylactic antibiotics 1+ Platelet Units ................................. - 0.0% 29.4% 11.1% 9.4% 4 Prophylactic antibiotics discontinued within 48 hours Missing .................................................. - 0.0% 0.0% 0.1% 0.3% AV Replace -- 52

47. Isolated Aortic Valve Replacement Procedures Data Summary Participant 30863 STS Period Ending 09/30/2017 2017 is a partial year: Jan 2017 - Sept 2017 Participant 30863 Like Group STS 2015 2016 2017 2017 2017 Intraop/Postop Blood Products Used ........ - 100.0% 82.4% 48.1% 41.3% Total Number of Blood Product Units 1 Red Blood Cell Unit ......................... - 0.0% 11.8% 9.8% 9.6% 2 Red Blood Cell Units ....................... - 0.0% 5.9% 12.7% 10.0% 3 Red Blood Cell Units ....................... - 0.0% 11.8% 5.4% 4.5% 4+ Red Blood Cell Units ..................... - 100.0% 41.2% 12.0% 8.9% 1+ Fresh Frozen Plasma Units ........... - 0.0% 58.8% 19.8% 15.6% 1+ Cryoprecipitate Units ..................... - 100.0% 58.8% 9.6% 9.4% 1+ Platelet Units ................................. - 100.0% 58.8% 24.9% 21.6% Missing .................................................. - 0.0% 0.0% 0.0% 0.0% Ventilation Total Ventilation Hours Mean .................................................. - 19.5 14.1 18.4 15.4 Median ............................................... - 19.5 6.0 5.6 5.3 25th Percentile .................................... - 19.5 4.5 3.7 3.6 75th Percentile .................................... - 19.5 20.5 10.9 9.0 Initial Ventilation Hours Mean .................................................. - 19.5 13.6 12.9 11.3 Median ............................................... - 19.5 5.6 5.5 5.2 Initial Ventilation <6 hours1 ................. - 0.0% 52.9% 55.1% 59.4% Extubated in OR .................................... - 0.0% 17.6% 2.9% 2.8% Missing .................................................. - 0.0% 0.0% 0.1% 0.3% Reintubation .......................................... - 0.0% 11.8% 4.3% 3.2% Missing .................................................. - 0.0% 0.0% 0.2% 0.4% Additional Ventilation Hours2 Mean .................................................. - - 4.0 126.8 129.7 Median ............................................... - - 4.0 65.0 65.0 ICU Stay Total ICU Hours 2 Among patients reintubated Mean .................................................. - 121.9 167.3 84.9 68.0 Median ............................................... - 121.9 137.3 53.9 46.3 25th Percentile .................................... - 121.9 114.4 31.2 25.0 75th Percentile .................................... - 121.9 194.2 98.0 74.8 AV Replace -- 53

Outcomes for cardiac surgery at Mt. View 2017

Robert Poston

Outcomes for cardiac surgery at Mt. View 2017